Survodutide
Aliases: BI 456906 · GLP-1/GCGR dual agonist
Survodutide is a linear peptide targeting GLP-1R, Glucagon receptor, developed by Boehringer Ingelheim and Zealand Pharma for multiple indications. As of Aug 15, 2024, its highest verified stage is Phase 2.
Phase 2· verified Aug 15, 2024
Identity
- Generic name
- survodutide
- Brand names
- —
- Development codes
- BI 456906
- Sponsor / originator
- Boehringer IngelheimZealand Pharma
- Targets
- GLP-1RGlucagon receptor
- Route / formulation
- Subcutaneous injection
Development timeline
- Phase 2· NASH/MASH· Global
As of Aug 15, 2024 · Confidence: high
Source: Phase 2 NASH trial of survodutide in adults with MASHSurvodutide phase 2 NASH/MASH trial active.
Trials
View all →| Registry ID | Phase | Status | Enrollment | Completion |
|---|---|---|---|---|
| NCT05649174 | Phase 2 | Active, not recruiting | 250 | Dec 1, 2025 |
Deals
View all →Sources
- registryprimary record
Phase 2 NASH trial of survodutide in adults with MASH
Boehringer Ingelheim International GmbH · ClinicalTrials.gov · Nov 3, 2022 · NCT05649174